Emerging Options and Sequencing Therapies for Relapsed Multiple Myeloma
Promising clinical responses have even been seen in heavily pretreated patients, suggesting that the new therapeutic options benefit those who have exhausted all traditional lines of therapy.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Bone Health in Patients with Hematologic Malignancies
Many patients with hematologic malignancies are at risk for treatment-induced bone loss which in turn can result in pathologic fractures, hypercalcemia, bone pain, and decline in motility and performance status.
Category
  • Hematologic Malignancies
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Lymphoma
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of CLL: Histologic Transformation and Relapsed/Refractory Disease
Histologic transformation of chronic lymphocytic leukemia (CLL) to more aggressive lymphoma is associated with a poor prognosis since it is typically resistant to standard chemoimmunotherapy regimens used for the treatment of CLL.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates to Front-line Therapy in Hodgkin Lymphoma
Patients with advanced Hodgkin lymphoma (HL) have limited options.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Emerging Options for the Management of Relapsed/Refractory Hodgkin Lymphoma
Patients with relapsed or refractory Hodgkin lymphoma (R/R HL) have limited therapeutic options, which are further narrowed once they become unresponsive to stem cell transplant.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Breast Cancer, Version 3.2018
These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer.
Category
  • Breast Cancer
Format
  • Monograph/Journal Supplement
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • AAPA Category 1 CME credit
  • Participation
NCCN Guidelines® Insights - Acute Lymphoblastic Leukemia, Version 1.2019
Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy.
Category
  • Acute Lymphoblastic Leukemia
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Survivorship, Version 2.2019
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of cancer and cancer treatment to aid healthcare professionals who work with survivors of adult-onset cancer.
Category
  • Survivorship
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Insights - Ovarian Cancer, Version 1.2019
Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis.
Category
  • Ovarian Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages